Scilex
Scilex
SCLX
NASDAQ
1.87
USD
-1.06%
About
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.
It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.0M |
| Three Month Average Volume | 27.1M |
| High Low | |
| Fifty-Two Week High | 6.55 USD |
| Fifty-Two Week Low | 0.7316 USD |
| Fifty-Two Week High Date | 03 Aug 2023 |
| Fifty-Two Week Low Date | 10 May 2024 |
| Price and Volume | |
| Current Price | 1.94 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 16.55% |
| Thirteen Week Relative Price Change | 33.09% |
| Twenty-Six Week Relative Price Change | -8.18% |
| Fifty-Two Week Relative Price Change | -73.72% |
| Year-to-Date Relative Price Change | -19.22% |
| Price Change | |
| One Day Price Change | -1.52% |
| Thirteen Week Price Change | 45.86% |
| Twenty-Six Week Price Change | 7.78% |
| Five Day Price Change | 3.19% |
| Fifty-Two Week Price Change | -67.28% |
| Year-to-Date Price Change | -4.90% |
| Month-to-Date Price Change | 0.52% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.72911 USD |
| Book Value Per Share (Most Recent Quarter) | -1.78839 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -2.22869 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -2.24955 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.8481 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.35874 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.39045 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.28149 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.27592 USD |
| Normalized (Last Fiscal Year) | -1.28149 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.28149 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.27592 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.28149 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.27592 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.0392 USD |
| Cash Per Share (Most Recent Quarter) | 0.01713 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.24967 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.29853 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.03356 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -9 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -229.46% |
| Pretax Margin (Last Fiscal Year) | -244.57% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 66.45% |
| Gross Margin (Trailing Twelve Months) | 66.14% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -225.55% |
| Operating Margin (Trailing Twelve Months) | -211.36% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -244.59% |
| Net Profit Margin (Trailing Twelve Months) | -229.47% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2.85% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 12.54% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 25.66% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -9.65% |
| EPS Change (Trailing Twelve Months) | -306.80% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 107.4M |
| Net Debt (Last Fiscal Year) | 121.5M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 8 |
| Price to Sales (Trailing Twelve Months) | 7 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 0 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -21,037,000 |
| Free Cash Flow (Trailing Twelve Months) | -4,044,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -12 |
| Net Interest Coverage (Trailing Twelve Months) | -12 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -121.73% |
| Return on Assets (Trailing Twelve Months) | -121.78% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -99,999.99% |